Innovative R&D
4
4 R&D institutions at home and abroad
600+
600+ outstanding R&D personnel
150
150+ new drugs in R&D
19
19 innovative patented drugs
Innovative R&D is the core competence of Sihuan Pharmaceutical.
With 4 R&D institutions at home and abroad, it invests More than 10% of annual sales revenue into R&D, and has 600+ outstanding R&D personnel. Under the leadership of senior scientists, it is committed to the R&D of innovative patented drugs and first-to-market generic drugs. There are 150+ new drugs in R&D, including 19 innovative patented drugs.
Innovative Drug R&D Center - Xuanzhu Biotech
Xuanzhu Biopharma, an innovative drug subsidiary of Sihuan Pharmaceutical, is an innovative pharmaceutical company rooted in China, focusing on major diseases such as digestion, oncology and non-alcoholic steatohepatitis, and is committed to R&D, production and commercialization of a class of new drugs with core independent intellectual property rights to solve unmet clinical treatment needs. At the same time, the company has two major R&D systems of small molecule chemical drugs and large molecule biological drugs, dual engines promote the company's innovation and development, forming a rare product pipeline in China that covers various types of small molecule chemical drugs, monoclonal antibodies, bispecific antibodies, antibody conjugates and other types. With its strong R&D strength and innovation capabilities, Xuanzhu Biotech has continuously won many honorary titles, and has been selected into the "Forbes 2022 New Unicorn List", "2023 China Biomedical Technology Innovation Value List - Top 10 Most Growing Small Molecule Innovative Drug Enterprises", "2023 China Top 100 Pharmaceutical R&D Comprehensive Strength", "China Unicorn Enterprise", "2023 China Biomedical Leaders 100 List", " 2023 Top 50 Science and Technology Innovation Leaders in China's Pharmaceutical Industry", etc.
Innovative Biologics R&D Center - Huisheng Biopharma
Huisheng Biopharma is a biopharmaceutical company under Sihuan Pharmaceutical, focusing on diabetes and complications. After nine years of development, Huisheng Biotech has become one of the few biopharmaceutical companies in China that can achieve full product coverage in the field of diabetes and complications, and integrate R&D, production and sales. The company has a first-class and experienced R&D team in diabetes drugs, and the product pipeline includes more than 40 products, covering a full range of second-generation, third-generation, new insulin (covering basic, premixed and fast-acting product types), SGLT-2i and GLP-1a and other latest mechanism products and commonly used hypoglycemic and complication treatment drugs. Huisheng Biopharma is committed to provide full-process, all-round integrated treatment solutions for diabetic patients, serving patients and making health easier.
Beijing Aohe Pharmaceutical Research Institute
Founded in 2010, Beijing Ausho Pharmaceutical Research Institute Co., Ltd. is a high-tech enterprise specializing in drug development. It has been awarded the honors of Beijing Municipal High-tech Enterprise, Beijing Municipal Enterprise Science and Technology Research and Development Institution, Beijing Innovative Small and Medium-sized Enterprise, Beijing Science and Technology Small and Medium-sized Enterprise, and Beijing Intellectual Property Pilot Unit. With a total area of 11,750.68 square meters and an existing experimental area of more than 9,000 square meters, the Institute has built an international leading synthesis, preparation and analysis laboratory, equipped with HPLC-MS, GC-MS, ICP-MS, HPLC, GC, Pre-HPLC, SEM, IC, NMR, XRPD, DSC/TGA and other advanced testing equipment, which can carry out quality research required for drug registration in an all-round way. With the development concept of "people-oriented and advocating science", the Institute is deeply engaged in the research and development of the first generic drugs, generic drugs, and varieties urgently needed in clinical practice in the fields of cardiovascular and cerebrovascular, tumor, digestive system, and psychiatric nerves. Through more than 10 years of accumulation, the institute has rich experience in the research and development of generic drugs, which can not only provide complete raw material and preparation research and development services, but also undertake modular commissioned services (such as elemental impurity research, genotoxic substance research, reverse engineering, impurity separation and purification, etc.), and can provide high-quality and efficient technical services and pharmaceutical-related products for companies and partners in need.
Clinical Development Center
Founded in 2013, Sihuan pharmaceutical's Clinical Development Center has established a business platform that runs through the entire process of clinical research and trial (covering various steps including clinical development strategy and path determination, clinical research/trial plan design, clinical trial process monitoring, clinical trial biostatistics, clinical trial data management, clinical trial report writing, and clinical evaluation reporting). By hiring more than 100 senior clinical researchers in the global pharmaceutical industry, the Clinical Development Center is responsible for promoting clinical research of all Class 1.1 innovative drugs, generic drugs and marketed drugs independently developed and introduced by the Group. At present, it has more than 50 ongoing clinical projects.
Medical Aesthetics R&D platform
Meiyen Laboratory: In 2021, Sihuan Pharma established the Meiyen Laboratory, a medical aesthetic product research institute in Southern California, USA, which is committed to introducing innovative technologies and independently developing a new generation of biomaterials and related medical aesthetic products, which has developed products including human genetic recombinant type III collagen. Beijing Medical Aesthetic R&D Center: Miyan Space, a medical aesthetic company under Sihuan Pharmaceutical, has established a R&D center in Beijing to improve existing medical aesthetic products and explore new applications. At the same time, it has in-depth cooperation with many well-known scientific research institutes and universities in China.